The Global Treatment for Neglected Tropical Disease market is expected to grow at a CAGR of 7.3% in the second half of the forecast period. The Global Treatment for Neglected Tropical Disease market reached $1.5bn in 2016, dominated by the treatments for malaria which held 30% share of the market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 157-page report you will receive 71 tables and 80 figures– all unavailable elsewhere.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Treatment for Neglected Tropical Disease market forecasts from 2019-2029
• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by disease type: – Malaria treatments – Dengue treatments – Leishmaniasis – Schistosomiasis – Lymphatic Filariasis – Chagas Disease – Others
For each disease type, the report provides a SWOT analysis, a list of selected drugs and revenueforecasts from 2019-2029 of the leading drugs.
• This report provides revenue forecast for these leading drugs: – Coartem (Novartis) – Clindamycin (Pfizer) – Dengvaxia (Sanofi) – AmBisome (Gilead Sciences) – Impavido (Knight Therapeutics) – ALBENZA (Amedra Pharmaceuticals LLC)
• This report also breaks down the revenue forecast for the Global Treatment for Neglected Tropical Disease market by regional and national market: – North America: US and Canada – Europe: Germany, the UK, France, Spain, Italy, Rest of Europe – Asia-Pacific: Japan, China, India, Rest of Asia – Latin America: Brazil, Mexico, Rest of Latin America – Middle East & Africa: Saudi Arabia, South of Africa, Rest of Middle East & Africa
Each regional market is further broken down by disease type.
• This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the neglected tropical disease market: – Pfizer, Inc. – Bayer – GlaxoSmithKline plc – Merck & Co., Inc. – Novartis International AG – Takeda Pharmaceutical Company Ltd – Sanofi S.A. – Eisai Co., Ltd
Buy our report today Global Treatment for Neglected Tropical Disease Market 2019-2029: Malaria, Dengue, Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Global Treatment for Neglected Tropical Disease Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Treatment for Neglected Tropical Disease Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Treatment for Neglected Tropical Disease
2.1 An Introduction to Treatment for Neglected Tropical Disease
2.2. Malaria Treatments
2.3. Dengue Treatments
2.4. Leishmaniasis
2.5 Schistosomiasis
2.6 Lymphatic Filariasis
2.7 Chagas Disease
2.8. Drivers
2.8.1. Increasing prevalence of various neglected tropical disease
2.8.2. Product Launch and Government Initiatives
2.9. Restrains
2.9.1 High Possibilities of Side Effect of Vaccine
3. Global Treatment for Neglected Tropical Disease Market 2019-2029
3.1 Global Treatment for Neglected Tropical Disease Market Forecast 2019-2029
3.2 Changing Market Shares by Segment2019-2029
3.3 Global Malaria Treatments Segment Market: Sales Forecast 2019-2029
3.3.1. Leading Drugs in the Malaria Treatments Market
3.3.1.1. Coartem (Novartis)
3.3.1.2. Clindamycin (Pfizer, Inc.)
3.3.1.3. Other Malaria Drugs
3.3.2. SWOT Analysis of the Malaria Treatments Market, 2019-2029
3.3.2.1. Strength
3.3.2.1.1. Supportive Government policy for Primary Health Care strategies
3.3.2.2. Weakness
3.3.2.2.1. Inadequacies in public health infrastructure, including training facilities
3.3.2.3. Opportunity
3.3.2.3.1. Increasing prevalence of Malaria
3.3.2.4. Threat
3.3.2.4.1. Community resistance to surveillance activities
3.4 Global Dengue treatments Segment Market: Sales Forecast 2019-2029
3.4.1. Dengvaxia (Sanofi)
3.4.2. SWOT Analysis of the Dengue Treatments Market, 2019-2029
3.4.2.1. Strength
3.4.2.1.1. Approval of Dengvaxia
3.4.2.2. Weakness
3.3.2.2.1. Vaccine is not available worldwide
3.4.2.3. Opportunity
3.4.2.3.1. Increasing prevalence of Dengue
3.4.2.4. Threat
3.4.2.4.1. Side Effects of Dengvaxia
3.5 Global Leishmaniasis Segment Market: Sales Forecast 2019-2029
3.5.1. AmBisome (Gilead Sciences)
3.5.2. Impavido (Marketed by Knight Therapeutics)
3.5.3. Leishmaniasis Drugs
3.5.4. SWOT Analysis of the Leishmaniasis Market, 2019-2029
3.5.4.1. Strength
3.5.4.1.1. Availability of vaccines
3.5.4.2. Weakness
3.5.4.2.1. No or less prevalence in developed regions
3.5.4.3. Opportunity
3.5.4.3.1. Increasing Prevalence of Visceral leishmaniasis
3.5.4.4. Threat
3.5.4.4.1. Patient don’t know if they are infected
3.6 Global Schistosomiasis Segment Market: Sales Forecast 2019-2029
3.6.1. SWOT Analysis of the Schistosomiasis Market, 2019-2029
3.6.1.1. Strength
3.6.1.1.1. Increasing prevalence of Schistosomiasis
3.6.1.2. Weakness
3.6.1.2.1. No or less prevalence in North America and Europe
3.6.1.3. Opportunity
3.6.1.3.1. Major patient base in Middle East & Africa
3.6.1.4. Threat
3.6.1.4.1. New Entrants
3.7 Global Lymphatic Filariasis Segment Market: Sales Forecast 2019-2029
3.7.1. ALBENZA (Amedra Pharmaceuticals LLC)
3.7.2. Lymphatic Filariasis Drugs
3.7.3. SWOT Analysis of the Lymphatic Filariasis Market, 2019-2029
3.7.3.1. Strength
3.7.3.1.1. Increasing number of patient treated with lymphatic filariasis
3.7.3.2. Weakness
3.7.3.2.1. Availability of vaccine for the patients
3.7.3.3. Opportunity
3.7.3.3.1. Increasing prevalence of Lymphatic Filariasis
3.7.3.4. Threat
3.7.3.4.1. Side Effects of ALBENZA
3.8 Global Chagas Disease Segment Market: Sales Forecast 2019-2029
3.8.1. Chagas Disease Drugs
3.8.2. SWOT Analysis of the Chagas Disease Market, 2019-2029
3.8.2.1. Strength
3.8.2.1.1. Increasing prevalence rate of underdiagnosed migrants
3.8.2.2. Weakness
3.8.2.2.1. Low prevalence of Chagas Disease in Asia-Pacific and Middle East & Africa
3.8.2.3. Opportunity
3.8.2.3.1. Increasing prevalence of Chagas Disease
3.8.2.4. Threat
3.8.2.4.1. Neglected by market players
3.9 Global Others Segment Market: Sales Forecast 2019-2029
4.Leading National Markets 2019-2029
4.1 Geographical Breakdown of the World Treatment for Neglected Tropical Disease Market
4.2 World Treatment for Neglected Tropical Disease Market: Regional Forecast 2019-2029
4.2.1 How Will Regional Market Shares Change to 2029?
5. North America Treatment for Neglected Tropical Disease Market 2019-2029
5.1. U.S. Treatment for Neglected Tropical Disease Market: Trends and Developments
5.2. Canada Treatment for Neglected Tropical Disease Market: Trends and Developments
6. Europe Treatment for Neglected Tropical Disease Market 2019-2029
6.1. Germany Treatment for Neglected Tropical Disease Market Forecast 2019-2029
6.2. France Treatment for Neglected Tropical Disease Market Forecast 2019-2029
6.3. U.K. Treatment for Neglected Tropical Disease Market Forecast 2019-2029
6.4. Italy Treatment for Neglected Tropical Disease Market Forecast 2019-2029
6.5. Spain Treatment for Neglected Tropical Disease Market Forecast 2019-2029
6.6. Rest of Europe Treatment for Neglected Tropical Disease Market Forecast 2019-2029
7. Asia-Pacific Treatment for Neglected Tropical Disease Market 2019-2029
7.1. China Treatment for Neglected Tropical Disease Market: Trends and Developments
7.2. Japan Treatment for Neglected Tropical Disease Market: Trends and Developments
7.3. India Treatment for Neglected Tropical Disease Market: Trends and Developments
7.4. Rest of Asia-Pacific Treatment for Neglected Tropical Disease Market: Trends and Developments
8. Latin America Treatment for Neglected Tropical Disease Market 2019-2029
8.1 Brazil Treatment for Neglected Tropical Disease Market: Trends and Developments
8.2. Mexico Treatment for Neglected Tropical Disease Market: Trends and Developments
8.3. Rest of Latin America Treatment for Neglected Tropical Disease Market: Trends and Developments
9. Middle East and Africa Treatment for Neglected Tropical Disease Market 2019-2029
9.1. Saudi Arabia Treatment for Neglected Tropical Disease Market Forecast 2019-2029
9.2. South Africa Treatment for Neglected Tropical Disease Market Forecast 2019-2029
9.3. Rest of Middle East and Africa Treatment for Neglected Tropical Disease Market Forecast 2019-2029
10. Leading Companies in the Treatment for Neglected Tropical Disease Market
10.1. Pfizer, Inc.
10.1.1 Pfizer, Inc.: Treatment for Neglected Tropical Disease Product Portfolio
10.1.2 Pfizer, Inc.: Financial Overview
10.1.3 Pfizer, Inc.: Recent Developments
10.2. Bayer AG
10.2.1 Bayer AG: Treatment for Neglected Tropical Disease Portfolio
10.2.2 Bayer AG: Financial Overview
10.2.3 Bayer AG: Recent Transactions Summary
10.3. GlaxoSmithKline plc
10.3.1 GlaxoSmithKline plc: Treatment for Neglected Tropical Disease Portfolio
Table 8.5 Rest of Latin America Treatment for Neglected Tropical Disease Market Forecast, 2019-2029 ($m, AGR %, CAGR %)
Table 9.1 Middle East and Africa Treatment for Neglected Tropical Disease Market Forecast, By Disease Type: Revenues ($m), AGR (%), CAGR (%), 2019-2029
Table 9.2 Middle East and Africa Treatment for Neglected Tropical Disease Market Forecast, by Country 2019-2029 ($m, AGR %, CAGR %)
Table 9.3 Saudi Arabia Treatment for Neglected Tropical Disease Market Forecast, 2019-2029 ($m, AGR %, CAGR %)
Table 9.4 South Africa Treatment for Neglected Tropical Disease Market Forecast, 2019-2029 ($m, AGR %, CAGR %)
Table 9.5 Rest of MEA Treatment for Neglected Tropical Disease Market Forecast, 2019-2029 ($m, AGR %, CAGR %)
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
